Aging increases the susceptibility of cisplatin-induced nephrotoxicity

Age

Volumn 37, Issue 6, 2015, Pages 1-13

  Wen, Jiagen ^a,b   Zeng, Meizi ^a   Shu, Yan ^c   Guo, Dong ^a,b   Sun, Yi ^d   Guo, Zhen ^a   Wang, Youhong ^a   Liu, Zhaoqian ^a,b   Zhou, Honghao ^a,b   Zhang, Wei ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Hunan Key Laboratory of Pharmacogenetics   (China)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^d CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Cisplatin; eGFR; Inflammatory response; Nephrotoxicity; Nrf2; Transporters

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; PACLITAXEL; PEMETREXED; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT;

ADULT; AGED; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CHINESE; CONTROLLED STUDY; DISEASE PREDISPOSITION; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOUSE; NEPHROTOXICITY; NONHUMAN; AGE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; KIDNEY; KIDNEY DISEASE; LUNG NEOPLASMS;

AGE FACTORS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS; CARBOPLATIN; CISPLATIN; DISEASE MODELS, ANIMAL; HUMANS; KIDNEY; KIDNEY DISEASES; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL;

EID: 84946402065     PISSN: 01619152     EISSN: 15744647     Source Type: Journal    
DOI: 10.1007/s11357-015-9844-3     Document Type: Article

References (40)

1. Aleksunes LM, Goedken MJ, Rockwell CE, Thomale J, Manautou JE, Klaassen CD (2010) Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. J Pharmacol Exp Ther 335(1):2–12
2. Anders HJ, Banas B, Schlondorff D (2004) Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 15(4):854–867
3. Anderson S, Brenner BM (1986) Effects of aging on the renal glomerulus. Am J Med 80(3):435–442
4. Argiris A, Li Y, Murphy BA, Langer CJ, Forastiere AA (2004) Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol 22(2):262–268
5. Badran HM, Elnoamany MF, Khalil TS, Eldin MM (2009) Age-related alteration of risk profile, inflammatory response, and angiographic findings in patients with acute coronary syndrome. Clin Med Cardiol 3:15–28
6. Cubillo A, Cornide M, Lopez JL, Molina R, Feliu J, Espinosa E, Zamora P, de Castro J, Ordonez A, Gonzalez Baron M (2001) Renal tolerance to cisplatin in patients 70 years and older. Am J Clin Oncol 24(2):192–197
7. Evans WE, Yee GC, Crom WR, Pratt CB, Green AA (1981) Clinical pharmacology of bleomycin and cisplatin. Head Neck Surg 4(2):98–110
8. Franke RM, Kosloske AM, Lancaster CS, Filipski KK, Hu C, Zolk O, Mathijssen RH, Sparreboom A (2010) Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase. Clin Cancer Res 16(16):4198–4206
9. Gautier JC, Riefke B, Walter J, Kurth P, Mylecraine L, Guilpin V, Barlow N, Gury T, Hoffman D, Ennulat D, Schuster K, Harpur E, Pettit S (2010) Evaluation of novel biomarkers of nephrotoxicity in two strains of rat treated with Cisplatin. Toxicol Pathol 38(6):943–956
10. Gounder SS, Kannan S, Devadoss D, Miller CJ, Whitehead KJ, Odelberg SJ, Firpo MA, Paine R 3rd, Hoidal JR, Abel ED, Rajasekaran NS (2012) Impaired transcriptional activity of Nrf2 in age-related myocardial oxidative stress is reversible by moderate exercise training. PLoS One 7(9):e45697
11. Iwata K, Aizawa K, Kamitsu S, Jingami S, Fukunaga E, Yoshida M, Yoshimura M, Hamada A, Saito H (2012) Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events. Clin Exp Nephrol 16(6):843–851
12. Li Q, Guo D, Dong Z, Zhang W, Zhang L, Huang SM, Polli JE, Shu Y (2013) Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs). Toxicol Appl Pharmacol 273(1):100–109
13. Loehrer PJ, Einhorn LH (1984) Cisplatin. Ann Intern Med 100(5):704–713
14. Mahrouf-Yorgov M, de L'hortet AC, Cosson C, Slama A, Abdoun E, Guidotti JE, Fromenty B, Mitchell C, Gilgenkrantz H (2011) Increased susceptibility to liver fibrosis with age is correlated with an altered inflammatory response. Rejuvenation Res 14(4):353–363
15. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P (2004) Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 24(3):307–315
16. Moscetti L, Nelli F, Padalino D, Sperduti I, Giannarelli D, Pollera CF (2005) Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer: impact of comorbidities on safety and efficacy outcome. J Chemother 17(6):685–692
17. Muhlberg W, Platt D (1999) Age-dependent changes of the kidneys: pharmacological implications. Gerontology 45(5):243–253
18. Nakamura T, Yonezawa A, Hashimoto S, Katsura T, Inui K (2010) Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem Pharmacol 80(11):1762–1767
19. Oda M, Koyanagi S, Tsurudome Y, Kanemitsu T, Matsunaga N, Ohdo S (2014) Renal circadian clock regulates the dosing-time dependency of cisplatin-induced nephrotoxicity in mice. Mol Pharmacol 85(5):715–722
20. Ozkok A, Edelstein CL (2014) Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int 2014:967826
21. Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73(9):994–1007
22. Pabla N, Murphy RF, Liu K, Dong Z (2009) The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Ren Physiol 296(3):F505–F511
23. Prasaja Y, Sutandyo N, Andrajati R (2015) Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia. Asian Pac J Cancer Prev 16(3):1117–1122
24. Ren J, Zhou Y, Zhang G, Zhou L, Zhao J, Wei Y, Wu X (2014) Role of age-related decrease of renal organic cation transporter 2 in the effect of atenolol on renal excretion of metformin in rats. Eur J Drug Metab Pharmacokinet
25. Sprowl JA, Gregorc V, Lazzari C, Mathijssen RH, Loos WJ, Sparreboom A (2012) Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy. Clin Pharmacol Ther 91(6):1022–1026
26. Sprowl JA, van Doorn L, Hu S, van Gerven L, de Bruijn P, Li L, Gibson AA, Mathijssen RH, Sparreboom A (2013) Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. Clin Pharmacol Ther 94(5):585–592
27. Swift ME, Burns AL, Gray KL, DiPietro LA (2001) Age-related alterations in the inflammatory response to dermal injury. J Investig Dermatol 117(5):1027–1035
28. Tanihara Y, Masuda S, Katsura T, Inui K (2009) Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. Biochem Pharmacol 78(9):1263–1271
29. The Jackson Laboratory. http://research.jax.org/faculty/harrison/ger1vLifespan1.html [11 Nov 2011]
30. Timaru-Kast R, Luh C, Gotthardt P, Huang C, Schafer MK, Engelhard K, Thal SC (2012) Influence of age on brain edema formation, secondary brain damage and inflammatory response after brain trauma in mice. PLoS One 7(8):e43829
31. Tzvetkov MV, Behrens G, O'Brien VP, Hohloch K, Brockmoller J, Benohr P (2011) Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms. Pharmacogenomics 12(10):1417–1427
32. van Vught LA, Endeman H, Meijvis SC, Zwinderman AH, Scicluna BP, Biesma DH, van der Poll T (2014) The effect of age on the systemic inflammatory response in patients with community-acquired pneumonia. Clin Microbiol Infect 20(11):1183–1188
33. Vermorken JB, van der Vijgh WJ, Klein I, Hart AA, Gall HE, Pinedo HM (1984) Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat Rep 68(3):505–513
34. Vermorken JB, van der Vijgh WJ, Klein I, Gall HE, van Groeningen CJ, Hart GA, Pinedo HM (1986) Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther 39(2):136–144
35. Vizeacoumar FJ, van Dyk N, Vizeacoumar FS, Cheung V, Li J, Sydorskyy Y, Case N, Li Z, Datti A, Nislow C, Raught B, Zhang Z, Frey B, Bloom K, Boone C, Andrews BJ (2010) Integrating high-throughput genetic interaction mapping and high-content screening to explore yeast spindle morphogenesis. J Cell Biol 188(1):69–81
36. Wen X, Buckley B, McCandlish E, Goedken MJ, Syed S, Pelis R, Manautou JE, Aleksunes LM (2014) Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice. Am J Pathol 184(5):1299–1308
37. Wolf J, Weinberger B, Arnold CR, Maier AB, Westendorp RG, Grubeck-Loebenstein B (2012) The effect of chronological age on the inflammatory response of human fibroblasts. Exp Gerontol 47(9):749–753
38. Zager RA, Johnson AC, Lund S, Randolph-Habecker J (2007) Toll-like receptor (TLR4) shedding and depletion: acute proximal tubular cell responses to hypoxic and toxic injury. Am J Physiol Ren Physiol 292:F304–F312
39. Zhang J, Zhou W (2012) Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. Food Chem Toxicol 50(7):2289–2293
40. Zhang B, Ramesh G, Uematsu S, Akira S, Reeves WB (2008) TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J Am Soc Nephrol 19(5):923–932